Magnetic Cell Selection System

FDA approved technology for the clinical selection of CD34+ cells, allowing the passive depletion of tumor cells from autologous apheresis products. A functionally closed system, automated technology giving high purity and yield of CD34+ cells.

The ISOLEX 300i Magnetic Cell Selection System is indicated for processing autologous peripheral blood progenitor cell (PBPC) products to obtain a CD34+ cell enriched population intended for hematopoietic reconstitution after myeloablative therapy in patients with CD34 negative tumors. ISOLEX processing reduces the number of non-CD34+ (non-target) cells, including tumor cells, in the autograft compared with unselected PBPC. Clinical studies have not determined whether use of the ISOLEX 300i system will alter progression-free or overall survival.